Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 7/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678448 | 0.94 | USP30 (0.47) | USP30BACE1BACE2LIPEAAK1 | |
| SCHEMBL27172752 | 0.84 | USP30 (0.42) | USP30BACE1BACE2AAK1DGAT1 | |
| SCHEMBL20508349 | 0.79 | USP30 (0.46) | USP30BACE1BACE2LIPEAAK1 | |
| SCHEMBL13069765 | 0.78 | USP30 (0.44) | USP30BACE1BACE2LIPEAAK1 | |
| SCHEMBL22789710 | 0.78 | USP30 (0.45) | USP30BACE1BACE2LIPEAAK1 | |
| SCHEMBL18013426 | 0.78 | USP30 (0.45) | USP30BACE1BACE2LIPEAAK1 | |
| SCHEMBL30205270 | 0.77 | USP30 (0.44) | USP30BACE1BACE2AAK1DGAT1 | |
| SCHEMBL30410847 | 0.76 | USP30 (0.39) | USP30LIPEAAK1DGAT1F2 | |
| SCHEMBL28950463 | 0.76 | USP30 (0.39) | USP30LIPEAAK1DGAT1F2 | |
| SCHEMBL16427738 | 0.76 | USP30 (0.49) | USP30BACE1BACE2AAK1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | USP30 1400/4885BACE1 3730/4885BACE2 3475/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | USP30 962/4885BACE1 2129/4885BACE2 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.